Tysabri ® (Natalizumab) ( DrugBank: Natalizumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01455220 (ClinicalTrials.gov) | January 2011 | 10/10/2011 | The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis | The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis | Multiple Sclerosis | Drug: Tysabri ® (Natalizumab) | University of South Florida | NULL | Completed | 18 Years | 60 Years | All | 45 | N/A | United States |